The TBD on CBD: FDA Public Hearing Highlights and Needed Actions

With the uptake of consumer CBD (cannabidiol) products rising at record growth rates, the need to assure consumers of product safety and transparency is of elevated importance.  The purpose of the FDA’s Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds public hearing on May 31, 2019 was to give consumers, academia, manufacturers, health care professionals, and other constituents the forum to share their knowledge and/or point of view on CBD, along with their input and/or recommendations to the FDA. Based on the presentations and comments made by manufacturers, Kline’s top three takeaways are as follows:Continue reading